Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talabostat and Docetaxel in Advanced NSCLC
NCT00080080Phase 2
Key facts
- Status
- Completed
- Countries
- 1
- Sponsor
- Point Therapeutics
- Modality
- Small Molecules
- Drugs
- talabostat
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of talabostat in non-small cell lung cancer (NSCLC), sponsored by Point Therapeutics. Primary endpoint: Objective Response Rate. Status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Talabostat + Docetaxel
Talabostat tablets + Docetaxel IV
03
Who it enrols
Patients with Stage IIIb/IV NSCLC who have failed a prior platinum-containing regimen, with measurable disease and ECOG 0-1.
04
Endpoints
Primary
Objective Response Rate
Secondary
Time to Tumor Progression
Overall Survival
Safety and Tolerability
Beyond the preview
Go deeper on NCT00080080.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080080.